Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

por Campioni, M., Agirrezabal, I., Hajek, R., Minarik, J., Pour, L., Spicka, I., Gonzalez-McQuire, S., Jandova, P., Maisnar, V.
Publicado 2019

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG...

por Mateos, M, Szarejko, M, Bila, J, Schjesvold, F, Spicka, I, Maisnar, V, Jurczyszyn, A, Grudeva-Popova, Z, Hajek, R, Usenko, G, Thuresson, M, Norin, S, Jarefors, S, Richardson, P, Pour, L
Publicado 2023

P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE

por Vlachová, M., Štork, M., Ševčíková, S., Jelínek, T., Minařík, J., Radocha, J., Krhovská, P., Pospíšilová, L., Špička, I., Straub, J., Pavlíček, P., Jungová, A., Sandecká, V., Maisnar, V., Hájek, R., Pour, L.
Publicado 2022

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

por Hájek, R, Masszi, T, Petrucci, M T, Palumbo, A, Rosiñol, L, Nagler, A, Yong, K L, Oriol, A, Minarik, J, Pour, L, Dimopoulos, M A, Maisnar, V, Rossi, D, Kasparu, H, Van Droogenbroeck, J, Yehuda, D B, Hardan, I, Jenner, M, Calbecka, M, Dávid, M, de la Rubia, J, Drach, J, Gasztonyi, Z, Górnik, S, Leleu, X, Munder, M, Offidani, M, Zojer, N, Rajangam, K, Chang, Y-L, San-Miguel, J F, Ludwig, H
Publicado 2017